Bio-Rad Laboratories, Inc.

BIO.B Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

379.50 15.35 +4.22%
Market cap
$10.3B
P/E
9.9×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
3.24
Beneish M
−2.29
Dividend safety
n/a

Bio-Rad Laboratories, Inc. 10-K filed Feb 13, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:50 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Feb 14, 2025: 1 added · 1 removed · 27 modified; 2 with only figures updated